ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "TESARO, Inc." (TSRO) Report Updated: Jul 28, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"TESARO, Inc." (TSRO)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Biotechnology
Competitors: GALT, CBMG, RGEN, ANAC

Stock Analysis

Rating: Monthly View

A
B
C
D
F
July August September October November December January February March April May June

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"TESARO, Inc."© quotemedia

Company Profile

TESARO, Inc., an oncology-focused biopharmaceutical company, engages in the identification, acquisition, development, and commercialization of oncology therapeutics and supportive care products in the United States, Europe, and other international markets. Its product portfolio consist of the Rolapitant, a neurokinin-1 receptor antagonist, which is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an orally active and potent poly polymerase inhibitor that has undergone a Phase I clinical trial in cancer patients; and TSR-011, an orally available anaplastic lymphoma kinase inhibitor, which is in Phase 1/2 dose escalation clinical trials in cancer patients. The company was founded in 2010 and is headquartered in Waltham, Massachusetts.

Recent News: "TESARO, Inc."